Validity of the CAPRA Score to Predict Biochemical Recurrence-Free Survival After Radical Prostatectomy. Results From a European Multicenter Survey of 1,296 Patients

May, Matthias; Knoll, Nina; Siegsmund, M.; Fahlenkamp, D.; Vogler, H; Hoschke, B.; Gralla, Oliver

doi:10.1016/j.juro.2007.07.043

Cited by 64 publications

(60 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second instrument, the UCSF Cancer of the Prostate Risk Assessment (CAPRA) score, assigns up to 3 points for Gleason score, up to 4 points for categorized PSA level, and 1 point each for age >50 years old, clinical stage T3a, and >33% positive of biopsy cores positive. The CAPRA score is thus calculated from 0 to 10, with every 2 point increase in CAPRA score representing roughly a doubling of risk of biochemical recurrence after prostatectomy [3,8,12]. …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

High-risk prostate cancer in the United States, 1990–2007

et al. 2008

View full text Add to dashboard Cite

Objectives-This study aimed to describe national trends in presentation, management, and outcomes for men with high risk prostate cancer. There has been no consistent risk migration within the high risk group over time. Treatment varies substantially with CAPRA score within the high risk group, with higher risk men less likely to receive local therapy. Use of androgen deprivation therapy has increased over time, both as primary therapy and in conjunction with both external beam radiation and brachytherapy. Biochemical outcomes vary according to CAPRA score within the high risk group. Methods-DataConclusions-Clinical stage T2c should not define high risk, and the high risk group should be substratified using a multivariable instrument. There is no evidence for meaningful downward risk migration among high-risk patients over the past 15 years. At least some men in the high risk group may be under-treated.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The CAPRA score can be categorized such that scores 0-2 indicated low risk, scores 3-5 indicate intermediate risk, and scores 6-10 indicated high risk [3,12]. Over the whole study period, 20.6% of the patients assigned to the high risk group by the standard definition had CAPRA scores 0-2, 43.5% had scores 3-5, and 35.9% had scores 6-10.…”

Section: Usingmentioning

confidence: 99%

High-risk prostate cancer in the United States, 1990–2007

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Most of these nomograms rely on various pretreatment variables to predict the likelihood of disease recurrence. The University of California, San Francisco, Cancer of the Prostate Risk Assessment (CAPRA) score predicts the risk of cancer recurrence with an accuracy as good as other available prediction instruments, can be calculated easily without the need for paper tables or computer software, and has been extensively validated in predicting recurrence [4][5][6][7][8][9][10][11][12], metastasis, and mortality across multiple treatment modalities [13].…”

Section: Introductionmentioning

confidence: 99%

Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy

et al. 2014

View full text Add to dashboard Cite

“…The UCSF-CAPRA incorporates the pre-operative PSA level, biopsy Gleason score, clinical T stage, percent of positive biopsies (PPB) and age to generate a score ranging from 0 to 10 points, with a greater score correlating with an increased risk of recurrence. The UCSF-CAPRA score has been validated externally and independently in both American and European cohorts (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

External Validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese Patients Receiving Radical Prostatectomy

Ishizaki

Hoque

Nishiyama

et al. 2011

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: In 2005, the University of California, San Francisco developed the Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score as a new risk stratification tool. The UCSF-CAPRA, which ranges from 0 to 10 points, consists of five clinical variables, prostate-specific antigen, Gleason score, T stage, percent of positive biopsies and age. The aim of this study was to validate the UCSF-CAPRA score for Japanese prostate cancer patients receiving radical prostatectomy using the contemporary Gleason grading. Methods: From 1999 to 2010, 211 men who underwent radical prostatectomy were used for validation. Biochemical progression-free survival was calculated using the Kaplan -Meier method and the UCSF-CAPRA and D'Amico risk categories were compared using the logrank method. The concordance index (c-index) for the UCSF-CAPRA and D'Amico risk classification was calculated. Results: Using the UCSF-CAPRA score, 85 (40.3%), 106 (50.2%) and 20 (9.5%) subjects were stratified as 0 -2 points (low risk), 3 -5 points (intermediate risk) and 6 -10 points (high risk). Using the D'Amico risk criteria, 66 (31.3%), 89 (42.2%) and 56 (26.5%) were stratified as low-, intermediate-and high-risk groups, respectively. The Kaplan -Meier analysis showed that the UCSF-CAPRA divided the patients significantly into each risk category. There was no significant difference between low and intermediate in the D'Amico risk classification. The c-index of the UCSF-CAPRA and D'Amico classification was 0.755 and 0.713, respectively. Conclusion: The UCSF-CAPRA is an acceptable risk category tool comparable to that of the D'Amico risk classification for Japanese prostate cancer patients receiving radical prostatectomy in the contemporary Gleason grading era.

show abstract

Validity of the CAPRA Score to Predict Biochemical Recurrence-Free Survival After Radical Prostatectomy. Results From a European Multicenter Survey of 1,296 Patients

Cited by 64 publications

References 12 publications

High-risk prostate cancer in the United States, 1990–2007

High-risk prostate cancer in the United States, 1990–2007

Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy

External Validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese Patients Receiving Radical Prostatectomy

Contact Info

Product

Resources

About